{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:15:15Z","timestamp":1781874915714,"version":"3.54.5"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,23]]},"abstract":"<jats:p>The development of nonalcoholic fatty liver disease (NAFLD) has been reported to be caused by sphingolipid family inducing insulin resistance, mitochondrial dysfunction, and inflammation, which can be regulated by multiple sphingolipid metabolic pathways. This study aimed to explore the molecular mechanism of crucial sphingolipid metabolism related genes (SMRGs) in NAFLD. Firstly, the datasets (GSE48452, GSE126848, and GSE63067) from the Gene Expression Omnibus database and sphingolipid metabolism genes (SMGs) from previous research were collected for this study. The differentially expressed genes (DEGs) between different NAFLD and controls were acquired through \u201climma,\u201d and the SMRGs were authenticated via weighted gene co-expression network analysis (WGCNA). After overlapping the DEGs and SMRGs, the causality between the intersection genes (DE-SMRGs) and NAFLD was explored to sort out the candidate biomarkers by Mendelian randomization (MR) study. The receiver operating characteristic (ROC) curves of candidate biomarkers in GSE48452 and GSE126848 were yielded to determine the biomarkers, followed by the nomogram construction and enrichment analysis. Finally, the immune infiltration analysis, the prediction of transcription factors (TFs) and drugs targeting biomarkers were put into effect. A total of 23 DE-SMRGs were acquired based on the differential analysis and weighted gene co-expression network analysis (WGCNA), of which 3 DE-SMRGs (CD37, CXCL9 and IL7R) were picked out for follow-up analysis through univariate and multivariate MR analysis. The values of area under ROC curve of CD37 and CXCL9 were &gt;0.7 in GSE48452 and GSE126848, thereby being regarded as biomarkers, which were mainly enriched in amino acid metabolism. With respect to the Spearman analysis between immune cells and biomarkers, CD37 and CXCL9 were significantly positively associated with M1 macrophages (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001), whose proportion was observably higher in NAFLD patients compared with controls. At last, TFs (ZNF460 and ZNF384) of CD37 and CXCL9 and a total of 79 chemical drugs targeting CD37 and CXCL9 were predicted. This study mined the pivotal SMRGs, CD37 and CXCL9, and systematically explored the mechanism of action of both biomarkers based on the public databases, which could tender a fresh reference for the clinical diagnosis and therapy of NAFLD.<\/jats:p>","DOI":"10.1097\/md.0000000000037185","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T21:06:45Z","timestamp":1708722405000},"page":"e37185","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Diagnostic value of sphingolipid metabolism-related genes CD37 and CXCL9 in nonalcoholic fatty liver disease"],"prefix":"10.1097","volume":"103","author":[{"given":"Jiayi","family":"Zhang","sequence":"first","affiliation":[{"name":"Queen Mary School, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfang","family":"Wang","sequence":"additional","affiliation":[{"name":"The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8747-6877","authenticated-orcid":false,"given":"Meixiu","family":"Jiang","sequence":"additional","affiliation":[{"name":"The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review.","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies.","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cld.2011.03.006","article-title":"The global epidemiology of hepatocellular carcinoma: present and future.","volume":"15","author":"McGlynn","year":"2011","journal-title":"Clin Liver Dis"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/MCG.0b013e3182872f29","article-title":"Epidemiology of hepatocellular carcinoma: consider the population.","volume":"47","author":"Mittal","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/liv.14478","article-title":"What\u2019s in a name? Renaming \u201cNAFLD\u201d to \u2018MAFLD\u2019.","volume":"40","author":"Fouad","year":"2020","journal-title":"Liver Int"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists.","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.32728","article-title":"The associations between modifiable risk factors and nonalcoholic fatty liver disease: a comprehensive Mendelian randomization study.","volume":"77","author":"Xie","year":"2023","journal-title":"Hepatology"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"3920196","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).","volume":"2020","author":"Tanase","year":"2020","journal-title":"J Diabetes Res"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2021.06.045","article-title":"Maternal obesity increases the risk and severity of NAFLD in offspring.","volume":"75","author":"Hagstr\u00f6m","year":"2021","journal-title":"J Hepatol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.3390\/ijms24076437","article-title":"Transcriptome sequencing reveals autophagy networks in rat livers during the development of NAFLD and identifies autophagy hub genes.","volume":"24","author":"Xie","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.21037\/atm-21-4824","article-title":"Application of single-cell RNA sequencing technology in liver diseases: a narrative review.","volume":"9","author":"He","year":"2021","journal-title":"Ann Transl Med"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease.","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/sj.leu.2402611","article-title":"Sphingosine 1-phosphate as a therapeutic agent.","volume":"16","author":"Spiegel","year":"2002","journal-title":"Leukemia"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.freeradbiomed.2021.02.016","article-title":"The role of ceramide accumulation in human induced pluripotent stem cell-derived cardiomyocytes on mitochondrial oxidative stress and mitophagy.","volume":"167","author":"Bekhite","year":"2021","journal-title":"Free Radic Biol Med"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.bcp.2006.12.023","article-title":"Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration.","volume":"73","author":"Glaros","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12933-015-0316-y","article-title":"Insulin treatment increases myocardial ceramide accumulation and disrupts cardiometabolic function.","volume":"14","author":"Hodson","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1478-3231.2007.01475.x","article-title":"Sphingolipid signalling and liver diseases.","volume":"27","author":"Mar\u00ed","year":"2007","journal-title":"Liver Int"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biochi.2018.07.021","article-title":"Sphingolipid metabolism in non-alcoholic fatty liver diseases.","volume":"159","author":"R\u00e9gnier","year":"2019","journal-title":"Biochimie"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7150\/ijbs.78525","article-title":"Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.","volume":"19","author":"Zhu","year":"2023","journal-title":"Int J Biol Sci"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.plipres.2014.01.004","article-title":"Ceramide: a simple sphingolipid with unique biophysical properties.","volume":"54","author":"Castro","year":"2014","journal-title":"Prog Lipid Res"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2007.01.002","article-title":"Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.","volume":"5","author":"Holland","year":"2007","journal-title":"Cell Metab"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/jcp.27058","article-title":"The effect of high-fat diet and inhibition of ceramide production on insulin action in liver.","volume":"234","author":"Zabielski","year":"2019","journal-title":"J Cell Physiol"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"635175","DOI":"10.3389\/fendo.2021.635175","article-title":"Sphingolipids as a culprit of mitochondrial dysfunction in insulin resistance and type 2 diabetes.","volume":"12","author":"Roszczyc-Owsiejczuk","year":"2021","journal-title":"Front Endocrinol"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fendo.2019.00665","article-title":"Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with non-alcoholic fatty liver disease.","volume":"10","author":"Jiang","year":"2019","journal-title":"Front Endocrinol"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.bbrc.2017.10.110","article-title":"Dihydroceramide is a key metabolite that regulates autophagy and promotes fibrosis in hepatic steatosis model.","volume":"494","author":"Lee","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.gastro.2017.03.022","article-title":"Sphingosine-1-phosphate prevents egress of hematopoietic stem cells from liver to reduce fibrosis.","volume":"153","author":"King","year":"2017","journal-title":"Gastroenterology"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cmet.2013.07.004","article-title":"DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery.","volume":"18","author":"Ahrens","year":"2013","journal-title":"Cell Metab"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"G462","DOI":"10.1152\/ajpgi.00358.2018","article-title":"Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.","volume":"316","author":"Suppli","year":"2019","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"e0124544","DOI":"10.1371\/journal.pone.0124544","article-title":"Integrative genomic signatures of hepatocellular carcinoma derived from nonalcoholic Fatty liver disease.","volume":"10","author":"Frades","year":"2015","journal-title":"PLoS One"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"1056310","DOI":"10.3389\/fendo.2022.1056310","article-title":"Machine learning to construct sphingolipid metabolism genes signature to characterize the immune landscape and prognosis of patients with uveal melanoma.","volume":"13","author":"Chi","year":"2022","journal-title":"Front Endocrinol"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies.","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data.","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis.","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data.","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"R38-20250503","first-page":"100141","article-title":"clusterProfiler 4.0: a universal enrichment tool for interpreting omics data.","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)"},{"key":"R39-20250503","doi-asserted-by":"crossref","first-page":"e34408","DOI":"10.7554\/eLife.34408","article-title":"The MR-base platform supports systematic causal inference across the human phenome.","volume":"7","author":"Hemani","year":"2018","journal-title":"eLife"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression.","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"key":"R41-20250503","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator.","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"key":"R42-20250503","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/ije\/dyx102","article-title":"Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption.","volume":"46","author":"Hartwig","year":"2017","journal-title":"Int J Epidemiol"},{"key":"R43-20250503","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10654-015-0011-z","article-title":"Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors.","volume":"30","author":"Burgess","year":"2015","journal-title":"Eur J Epidemiol"},{"key":"R44-20250503","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves.","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinf"},{"key":"R45-20250503","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.recesp.2011.01.019","article-title":"[Regression modeling strategies].","volume":"64","author":"N\u00fa\u00f1ez","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"R46-20250503","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT.","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"key":"R47-20250503","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"R48-20250503","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cmet.2021.06.006","article-title":"Sphingolipids in metabolic disease: the good, the bad, and the unknown.","volume":"33","author":"Green","year":"2021","journal-title":"Cell Metab"},{"key":"R49-20250503","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy.","volume":"18","author":"Ogretmen","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"R50-20250503","doi-asserted-by":"crossref","first-page":"G1102","DOI":"10.1152\/ajpgi.00095.2016","article-title":"Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance.","volume":"310","author":"Ilan","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R51-20250503","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/CM9.0000000000002156","article-title":"Bile acids and sphingolipids in non-alcoholic fatty liver disease.","volume":"135","author":"Jackson","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"R52-20250503","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1681\/ASN.2016010098","article-title":"Mendelian randomization as an approach to assess causality using observational data.","volume":"27","author":"Sekula","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R53-20250503","doi-asserted-by":"crossref","first-page":"9531","DOI":"10.3390\/ijms21249531","article-title":"CD37 in B cell derived tumors-more than just a docking point for monoclonal antibodies.","volume":"21","author":"Bobrowicz","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R54-20250503","doi-asserted-by":"crossref","first-page":"1202725","DOI":"10.3389\/fimmu.2023.1202725","article-title":"Prognostic and immunological significance of an M1 macrophage-related gene signature in osteosarcoma.","volume":"14","author":"Mao","year":"2023","journal-title":"Front Immunol"},{"key":"R55-20250503","doi-asserted-by":"crossref","first-page":"103249","DOI":"10.1016\/j.isci.2021.103249","article-title":"The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas.","volume":"24","author":"Yan","year":"2021","journal-title":"iScience"},{"key":"R56-20250503","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/13543784.2018.1427730","article-title":"Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies.","volume":"27","author":"Witkowska","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"R57-20250503","doi-asserted-by":"crossref","first-page":"BSR20200008","DOI":"10.1042\/BSR20200008","article-title":"CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia.","volume":"40","author":"Zhang","year":"2020","journal-title":"Biosci Rep"},{"key":"R58-20250503","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hep.27087","article-title":"Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice.","volume":"60","author":"Ikeda","year":"2014","journal-title":"Hepatology"},{"key":"R59-20250503","first-page":"4845","article-title":"CXCL9 regulates acetaminophen-induced liver injury via CXCR3.","volume":"18","author":"Song","year":"2019","journal-title":"Exp Ther Med"},{"key":"R60-20250503","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-030-36667-4_5","article-title":"The multifaceted roles of CXCL9 within the tumor microenvironment.","volume":"1231","author":"Neo","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"R61-20250503","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-230X-13-120","article-title":"The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis.","volume":"13","author":"Semba","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"R62-20250503","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep4.1789","article-title":"Distinct hepatic gene-expression patterns of NAFLD in patients with obesity.","volume":"6","author":"Subudhi","year":"2022","journal-title":"Hepatol Commun"},{"key":"R63-20250503","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40169-017-0156-3","article-title":"CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study.","volume":"6","author":"Jim\u00e9nez-Sousa","year":"2017","journal-title":"Clin Transl Med"},{"key":"R64-20250503","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3934\/mbe.2020070","article-title":"The role of CXC cytokines as biomarkers and potential targets in hepatocellular carcinoma.","volume":"17","author":"Wang","year":"2019","journal-title":"Math Biosci Eng"},{"key":"R65-20250503","doi-asserted-by":"crossref","first-page":"e15225","DOI":"10.7717\/peerj.15225","article-title":"Gypenosides ameliorate high-fat diet-induced nonalcoholic fatty liver disease in mice by regulating lipid metabolism.","volume":"11","author":"Zhou","year":"2023","journal-title":"PeerJ"},{"key":"R66-20250503","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/03602532.2023.2202359","article-title":"The alteration of drug metabolism enzymes and pharmacokinetic parameters in nonalcoholic fatty liver disease: current animal models and clinical practice.","volume":"55","author":"Zhu","year":"2023","journal-title":"Drug Metab Rev"},{"key":"R67-20250503","doi-asserted-by":"crossref","first-page":"1034494","DOI":"10.3389\/fendo.2022.1034494","article-title":"Transcriptomic profiling of hepatic tissues for drug metabolism genes in nonalcoholic fatty liver disease: a study of human and animals.","volume":"13","author":"Chen","year":"2022","journal-title":"Front Endocrinol"},{"key":"R68-20250503","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R69-20250503","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.3390\/ijms23084325","article-title":"Role of branched-chain amino acid metabolism in type 2 diabetes, obesity, cardiovascular disease and non-alcoholic fatty liver disease.","volume":"23","author":"Cuomo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R70-20250503","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hep.29465","article-title":"Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance.","volume":"67","author":"Gaggini","year":"2018","journal-title":"Hepatology"},{"key":"R71-20250503","doi-asserted-by":"crossref","first-page":"eaaz2841","DOI":"10.1126\/scitranslmed.aaz2841","article-title":"Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome.","volume":"12","author":"Rom","year":"2020","journal-title":"Sci Transl Med"},{"key":"R72-20250503","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2023.02.033","article-title":"Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.","volume":"79","author":"Yahoo","year":"2023","journal-title":"J Hepatol"},{"key":"R73-20250503","doi-asserted-by":"crossref","first-page":"112801","DOI":"10.1016\/j.yexcr.2021.112801","article-title":"MIG\/CXCL9 exacerbates the progression of metabolic-associated fatty liver disease by disrupting Treg\/Th17 balance.","volume":"407","author":"Li","year":"2021","journal-title":"Exp Cell Res"},{"key":"R74-20250503","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41574-022-00675-6","article-title":"Macrophage functional diversity in NAFLD - more than inflammation.","volume":"18","author":"Barreby","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"R75-20250503","doi-asserted-by":"crossref","first-page":"107823","DOI":"10.1016\/j.intimp.2021.107823","article-title":"Anti-inflammatory and M2 macrophage polarization-promoting effect of mesenchymal stem cell-derived exosomes.","volume":"97","author":"Arabpour","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R76-20250503","doi-asserted-by":"crossref","first-page":"1038401","DOI":"10.3389\/fimmu.2022.1038401","article-title":"Single-cell RNA sequencing reveals a novel inhibitory effect of ApoA4 on NAFL mediated by liver-specific subsets of myeloid cells.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:32:19Z","timestamp":1746318739000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":76,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037185","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]}}}